Xiao, Yufeng published the artcileDiscovery of histone deacetylase 3 (HDAC3)-specific PROTACs, Synthetic Route of 39115-95-2, the publication is Chemical Communications (Cambridge, United Kingdom) (2020), 56(68), 9866-9869, database is CAplus and MEDLINE.
Histone deacetylases (HDACs) are validated drug targets for cancer treatment. Increased HDAC isoenzyme selectivity and novel strategies to inhibit HDAC activity could lead to safer and more effective drug candidates. Nonetheless, it is quite challenging to develop isoenzyme-specific HDACi due to the highly conserved catalytic domain. We discovered XZ9002, a first-in-class HDAC3-specific PROTAC that potently degraded HDAC3. Importantly, XZ9002 is more effective to inhibit cancer cell proliferation than its proteolysis-inactive counterpart, suggesting HDAC3 degradation is a novel and promising anticancer approach.
Chemical Communications (Cambridge, United Kingdom) published new progress about 39115-95-2. 39115-95-2 belongs to iodides-buliding-blocks, auxiliary class Iodide,Hydrazine,Amine,Benzene,Hydrazide,Amide, name is 4-Iodobenzohydrazide, and the molecular formula is C4H3Cl2N3, Synthetic Route of 39115-95-2.
Referemce:
https://en.wikipedia.org/wiki/Iodide,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com